Literature DB >> 18667005

Potential of resveratrol in anticancer and anti-inflammatory therapy.

Chibuike C Udenigwe1, Vanu R Ramprasath, Rotimi E Aluko, Peter J H Jones.   

Abstract

Phytochemicals present in food have shown significant prospects in the treatment and management of a vast array of human diseases. Resveratrol is a stilbene-type aromatic phytoalexin predominantly found in grapes, peanuts, berries, turmeric, and other food products. Resveratrol has been reported to exhibit several physiological activities including anticancer and anti-inflammatory activities in vitro and in experimental animal models, as well as in humans. Anticancer activity of this compound is mainly due to induction of apoptosis via several pathways, as well as alteration of gene expressions, all leading to a decrease in tumor initiation, promotion, and progression. Resveratrol exhibits anti-inflammatory activity through modulation of enzymes and pathways that produce mediators of inflammation and also induction of programmed cell death in activated immune cells. Resveratrol has been shown to produce no adverse effects, even when consumed at high concentrations. Hence, resveratrol possesses good potential to be used as an adjunctive or alternative therapy for cancer and inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667005     DOI: 10.1111/j.1753-4887.2008.00076.x

Source DB:  PubMed          Journal:  Nutr Rev        ISSN: 0029-6643            Impact factor:   7.110


  57 in total

1.  Resveratrol suppresses colitis and colon cancer associated with colitis.

Authors:  Xiangli Cui; Yu Jin; Anne B Hofseth; Edsel Pena; Joshua Habiger; Alexander Chumanevich; Deepak Poudyal; Mitzi Nagarkatti; Prakash S Nagarkatti; Udai P Singh; Lorne J Hofseth
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-23

Review 2.  Addressing Facts and Gaps in the Phenolics Chemistry of Winery By-Products.

Authors:  Nelson F L Machado; Raúl Domínguez-Perles
Journal:  Molecules       Date:  2017-02-14       Impact factor: 4.411

3.  Sirtuin 1 attenuates inflammation and hepatocellular damage in liver transplant ischemia/Reperfusion: From mouse to human.

Authors:  Kojiro Nakamura; Shoichi Kageyama; Bibo Ke; Takehiro Fujii; Rebecca A Sosa; Elaine F Reed; Nakul Datta; Ali Zarrinpar; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Liver Transpl       Date:  2017-10       Impact factor: 5.799

4.  Quantum chemical and molecular mechanics studies on the assessment of interactions between resveratrol and mutant SOD1 (G93A) protein.

Authors:  E Srinivasan; R Rajasekaran
Journal:  J Comput Aided Mol Des       Date:  2018-10-28       Impact factor: 3.686

Review 5.  NRF2, cancer and calorie restriction.

Authors:  A Martín-Montalvo; J M Villalba; P Navas; R de Cabo
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

Review 6.  Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function.

Authors:  David O Kennedy; Emma L Wightman
Journal:  Adv Nutr       Date:  2011-01-10       Impact factor: 8.701

Review 7.  Mitochondrial function in hypoxic ischemic injury and influence of aging.

Authors:  P Benson Ham; Raghavan Raju
Journal:  Prog Neurobiol       Date:  2016-06-16       Impact factor: 11.685

8.  Neurobehavioural evaluation of resveratrol in murine models of anxiety and schizophrenia.

Authors:  Mohammed Garba Magaji; Loretta Oghenekome Iniaghe; Mutiat Abolarin; Opeyemi Isa Abdullahi; Rabiu Abdusalam Magaji
Journal:  Metab Brain Dis       Date:  2016-11-22       Impact factor: 3.584

Review 9.  The biological responses to resveratrol and other polyphenols from alcoholic beverages.

Authors:  Lindsay Brown; Paul A Kroon; Dipak K Das; Samarjit Das; Arpad Tosaki; Vincent Chan; Manfred V Singer; Peter Feick
Journal:  Alcohol Clin Exp Res       Date:  2009-06-10       Impact factor: 3.455

Review 10.  Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.